Breast Pathology and Cancer Diagnosis

Immunohistochemistry and Biomarkers in Breast Pathology

The track on "Immunohistochemistry and Biomarkers in Breast Pathology" focuses on the critical role of immunohistochemistry (IHC) and biomarkers in the diagnosis, prognosis, and treatment of breast pathology. This track explores the latest advancements in IHC techniques, including the identification and evaluation of key biomarkers such as hormone receptors (ER, PR), HER2/neu, Ki-67, and other emerging markers. Discussions will revolve around their clinical significance, interpretation challenges, and their impact on therapeutic decision-making. Additionally, this track will delve into novel biomarkers and their potential for risk assessment, predicting treatment response, and guiding personalized treatment strategies. Attendees will gain insights into the evolving landscape of IHC and biomarkers, enhancing their understanding of breast pathology evaluation and patient management.